Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2003 1
2004 2
2006 1
2010 1
2011 1
2012 1
2013 3
2014 1
2018 1
2019 1
2020 2
2021 4
2022 2
2023 2
2024 2
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study.
Tesi B, Robelius A, Baskin B, Lazarevic V, Deneberg S, Höglund M, Fogelstrand L, Ungerstedt J, Pandzic T, Tobiasson M, Garelius HG, Kuchinskaya E, Persson F, Ågerstam H, Hallböök H, Fioretos T, Nordin J, Norberg A, Thuresson AC, Lehmann S, Ladenvall C, Barbany G, Vennström L, Ejerblad E, Cavelier L, Cammenga J, Jädersten M, Hellström-Lindberg E, Baliakas P. Tesi B, et al. Among authors: ejerblad e. Clin Cancer Res. 2025 Jul 15;31(14):3062-3071. doi: 10.1158/1078-0432.CCR-24-4251. Clin Cancer Res. 2025. PMID: 40388595 Free PMC article.
Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, Olesen G, Björklund A, Olsnes Kittang A, Werlenius O, Lorentz F, Rasmussen B, Cammenga J, Weber D, Lindholm C, Wiggh J, Dimitriou M, Moen AE, Yip Lundström L, von Bahr L, Baltzer-Sollander K, Jädersten M, Kytölä S, Walldin G, Ljungman P, Groenbaek K, Mielke S, Jacobsen SEW, Ebeling F, Cavelier L, Smidstrup Friis L, Dybedal I, Hellström-Lindberg E. Tobiasson M, et al. Among authors: ejerblad e. J Clin Oncol. 2024 Apr 20;42(12):1378-1390. doi: 10.1200/JCO.23.01159. Epub 2024 Jan 17. J Clin Oncol. 2024. PMID: 38232336
Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes.
Creignou M, Bernard E, Gasparini A, Tranberg A, Todisco G, Moura PL, Ejerblad E, Nilsson L, Garelius H, Antunovic P, Lorenz F, Rasmussen B, Walldin G, Mortera-Blanco T, Jansson M, Tobiasson M, Elena C, Ferrari J, Gallì A, Pozzi S, Malcovati L, Edgren G, Crowther MJ, Jädersten M, Papaemmanuil E, Hellström-Lindberg E. Creignou M, et al. Among authors: ejerblad e. J Intern Med. 2024 Jul;296(1):53-67. doi: 10.1111/joim.13790. Epub 2024 Apr 23. J Intern Med. 2024. PMID: 38654517 Free article.
Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.
Rasmussen B, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Cavalier L, Ebeling F, Olsnes AM, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E, Schlegelberger B, Göhring G. Rasmussen B, et al. Among authors: ejerblad e. Genes Chromosomes Cancer. 2025 Feb;64(2):e70029. doi: 10.1002/gcc.70029. Genes Chromosomes Cancer. 2025. PMID: 39921387 Free PMC article. Clinical Trial.
Acetaminophen, aspirin, and chronic renal failure.
Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, Lipworth L, Elinder CG, Blot WJ, McLaughlin JK, Zack MM, Nyrén O. Fored CM, et al. Among authors: ejerblad e. N Engl J Med. 2001 Dec 20;345(25):1801-8. doi: 10.1056/NEJMoa010323. N Engl J Med. 2001. PMID: 11752356 Free article.
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E. Rasmussen B, et al. Among authors: ejerblad e. Leukemia. 2022 May;36(5):1436-1439. doi: 10.1038/s41375-022-01537-w. Epub 2022 Mar 11. Leukemia. 2022. PMID: 35277655 Free PMC article. Clinical Trial. No abstract available.
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
25 results